University of Pikeville

The Inner Circle acknowledges Lee C. Ferguson, DO, FACS as a Pinnacle Lifetime Member

Retrieved on: 
星期五, 四月 26, 2024
Congress, Chin Na, Society, University, Volunteering, Patient, American College, Aneurysm, Advanced cardiac life support, General surgery, University of Pikeville, American College of Surgeons, Moyamoya disease, RPVI, Varicose veins, FACS, ACLS, ACS, BLS, Medicine, Health, Basic life support, Inner circle, Elective surgery, Broad Street

MOBILE, Ala., April 26, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lee C. Ferguson, DO, FACS is acknowledged as a Pinnacle Lifetime Member for his contributions as a Vascular Surgeon.

Key Points: 
  • MOBILE, Ala., April 26, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lee C. Ferguson, DO, FACS is acknowledged as a Pinnacle Lifetime Member for his contributions as a Vascular Surgeon.
  • Dr. Ferguson, a distinguished dual board-certified vascular surgeon and endovascular specialist, has been transforming vascular care in Mobile, Alabama, and its surrounding regions.
  • He is a key member of Vascular Associates of South Alabama, LLC, renowned for his expertise in advanced, minimally invasive, endovascular techniques and traditional open surgery.
  • Dr. Ferguson's unwavering commitment to patient-centered care reflects his belief in treating each patient as he would want his own family to be treated.

Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States

Retrieved on: 
星期一, 十二月 18, 2023
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, DED, University of Pikeville, OD, FDA, Acquisition, Drainage, Optometry, Professional corporation, MD, University, Associate professor, P.C, Telecanthus, CPT, Patient, Hyaluronic acid, Pharmaceutical industry

Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).

Key Points: 
  • Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).
  • Nordic Pharma will launch and commercialize LACRIFILL in the U.S. and has been chosen because of its focus on Ophthalmology.
  • This acquisition will enhance Nordic Pharma’s impact on the global ophthalmology market starting with the U.S. launch of LACRIFILL, the patented therapy for DED.
  • “Visant is thrilled to be joining the Nordic Pharma group,” said Vartan Ghazarossian, Ph.D., Visant co-founder and CEO.

Community Trust Bancorp, Inc. Announces the Appointment of Dr. Lillian (Kay) Webb to Its Board of Directors

Retrieved on: 
星期二, 十二月 5, 2023
Finance, Consulting, Banking, Professional Services, Asset Management, Senior counsel, Ball State University, CTBI, Psychology, Learning, Student, Faculty, University of Pikeville, Music, Indiana Wesleyan University, University, Community, Education, Family, Northwest Nazarene University, Knowledge, Life, Olivet Nazarene University, Management

Community Trust Bancorp, Inc. (NASDAQ: CTBI) is pleased to announce the appointment of Dr. Lillian (Kay) Webb to its Board of Directors.

Key Points: 
  • Community Trust Bancorp, Inc. (NASDAQ: CTBI) is pleased to announce the appointment of Dr. Lillian (Kay) Webb to its Board of Directors.
  • Lillian (Kay) Webb, Ph.D., was born in Bedford, Indiana, into a family of educators who taught her the love of learning.
  • Dr. Webb pursued her passion for vocal performance in college at Olivet Nazarene University in Bourbonnais, Illinois.
  • At UPIKE, Dr. Webb assists and advises students as they explore career paths through college and beyond.

Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

Retrieved on: 
星期三, 十月 18, 2023
Patient, FDA, Cornea, Contact, Headache, Food, Presbyopia, Associate professor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FACS, Optometry, Night vision, University, Safety, Pilocarpine, Diagnosis, University of Pikeville, Pharmaceutical industry, Telescopic sight, Nursing

QLOSI is expected to be commercially available in the U.S. in the first half of 2024.

Key Points: 
  • QLOSI is expected to be commercially available in the U.S. in the first half of 2024.
  • "The FDA approval of QLOSI marks a tremendous milestone for Orasis as we continue our mission to provide a flexible treatment option for the millions of people in the U.S. living with presbyopia, or blurry near vision," said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals.
  • "I am grateful to the Orasis team, our strategic partners, clinical investigators, and patients who participated in our clinical trials, all of whom made this achievement possible."
  • QLOSI (pronounced CLOH-see) is a prescription eye drop that can be used daily, or as needed, up to twice per day.

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

Retrieved on: 
星期二, 七月 18, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, Surgery, Health, FDA, Clinical Trials, DED, Harald von Boehmer, University, Therapy, Patient satisfaction, Efficacy, Sheppard, Eye, Telecanthus, Pharmacokinetics, ASCRS, Multimedia, Inflammation, Cornea, Random phase approximation, Stinger, Ophthalmology, Acquisition, Oil, Patient, BID, Political moderate, University of Pikeville, Ciclosporin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Treatment, Food, JAMA Ophthalmology, Pharmaceutical industry, Safety

“VEVYE, which is expected to be available soon, is a unique cyclosporine formulation indicated for treatment of the signs and symptoms of DED.

Key Points: 
  • “VEVYE, which is expected to be available soon, is a unique cyclosporine formulation indicated for treatment of the signs and symptoms of DED.
  • In this study, VEVYE was shown to be safe, and no systemic exposure of cyclosporin was observed after ocular administration.
  • Schirmer’s tear test responses of ≥10 mm increase was statistically significantly higher in the VEVYE compared vehicle at Day 29.
  • Wirta DL, Krösser S, Long -Term Safety and Efficacy of a Water-Free Cyclosporine Ophthalmic Solution for the Treatment of Dry‑Eye Disease: ESSENCE-2-OLE study.

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Retrieved on: 
星期四, 五月 18, 2023
Biotechnology, FDA, Health, Pharmaceutical, Optical, Contact, DED, Cornea, Visual analogue scale, GOBI, Research and development, University, Therapy, Meibomian gland dysfunction, TCF Financial Corporation (1923–2019), VAS, Inflammation, History, Bausch & Lomb, Telecanthus, Development, Patient, Desiccation, University of Pikeville, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, MGD, Disease, Pharmaceutical industry, Telescopic sight, Birth control

MIEBO is the first and only FDA-approved treatment for DED that directly targets tear evaporation.

Key Points: 
  • MIEBO is the first and only FDA-approved treatment for DED that directly targets tear evaporation.
  • “Today’s FDA approval of MIEBO further advances DED treatment by addressing a significant unmet need for millions of people suffering with this disease,” said Brent Saunders, chairman and CEO, Bausch + Lomb.
  • “We are proud to bring to market the first and only prescription eye drop approved in the United States for the treatment of DED that directly targets evaporation.
  • “We are grateful to Bausch + Lomb for their continued collaboration in bringing this unique new treatment option to market.”
    MIEBO™ (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

A Healthier WE launches Appalachia Rising to facilitate first-ever Bi-County Task Force aimed at bringing healthier living to the region

Retrieved on: 
星期一, 四月 10, 2023
Community Hospitals and Wellness Centers, Partnership, University, Broken Hill Women's Memorial, Partnership for a Healthier America, II, DO, Stanford University School of Medicine, Scenic viewpoint, Community, Local, MD, SAN, University of Pikeville, Rural health, Holler, Community development, Entrepreneurship, Health, Tourism, Management

SAN FRANCISCO, April 10, 2023 /PRNewswire-PRWeb/ -- A Healthier WE, a non-profit organization, in partnership with leaders in two rural Appalachia counties, is pleased to announce a new bottom-up model of addressing rural health and well-being. Local leaders have identified area residents, local health and economic development leaders, as well as political leaders, who are willing to find opportunities for improving personal and community health. In addition, we have a growing and well-respected list of sponsors, and speakers.

Key Points: 
  • This inaugural Appalachian partnership-focused event is being held April 19, 2023, at the Overlook Event Center in Pikeville, Kentucky.
  • We look forward to forming critical relationships with the wide range of leaders who are committed to creating healthier rural communities."
  • Phil Polakoff, MD, CEO of A Healthier WE said "We are excited to partner with key stakeholders in rural health.
  • We look forward to forming critical relationships with leaders and change makers who are committed to creating healthier rural communities."

Launch Esports Announces First Slate of Div. II and NAIA Conferences Paving the Way for Collegiate Esports Structure and Continuity

Retrieved on: 
星期四, 八月 5, 2021
Electronic Games, Technology, Other Sports, Sports, Entertainment, Software, University, Data Management, Education, Sooner Athletic Conference, Red River Athletic Conference, University, MID, Student, Valorant, Commissioner, Bethel University, Third Division, Division, Organization, KCAC, Professional, Technology, League of Legends, Top Blokes Foundation, Cumberland University, NASCAR, Â, Partnership, Ottawa University, Bethany College, Kansas Wesleyan University, Shawnee State University, Campbellsville University, Psyonix, School, Community college, Conference Carolinas, Mid-South Conference, California Community College Athletic Association, Dallas Fuel, SPE, Ghost (game), The Walt Disney Company, Knowledge, League, Division II, Pikeville, Oklahoma Wesleyan University, NAIA, University of Pikeville, Conference, Video game, Mainline, Steel Planet Esports, MAINLINE, STEEL PLANET ESPORTS

Launch Esports provides competition infrastructure, broadcasting and management of esports rights for Division II, Division III, NAIA and community college conferences and universities, including KCAC, Mid-South Conference, Conference Carolinas, Sooner Athletic Conference, and Red River Athletic Conference.

Key Points: 
  • Launch Esports provides competition infrastructure, broadcasting and management of esports rights for Division II, Division III, NAIA and community college conferences and universities, including KCAC, Mid-South Conference, Conference Carolinas, Sooner Athletic Conference, and Red River Athletic Conference.
  • Launch Esports and its member conferences are focused on the massive untapped opportunity to reach a community at over 1,500 schools across the nation, said Darin David, President of Launch Esports.
  • Todays announcements are the first of many to come for Launch Esports as it rolls out its plans to bring professionalism and commercialization opportunities to collegiate esports.
  • Launch anticipates adding additional conferences to create continuity across various NAIA, Division II, Division III and Community College that want to feature traditional conference play among their member schools.